On-Demand

From Resistance to Recognition: Enhancing Care for Neuroendocrine and High-Risk Prostate Cancer Phenotypes

Neuroendocrine prostate cancer (NEPC) and other aggressive histologic variants of prostate cancer (PC) represent rare but clinically devastating disease phenotypes. These tumors progress rapidly and often evade detection through conventional measures such as PSA monitoring and…

Diagnosis and Multidisciplinary Care of VHL Disease–Associated Tumors

Von Hippel-Lindau (VHL) disease is associated with a range of tumor types that require timely recognition and coordinated management. Accurate diagnosis depends on careful evaluation of clinical presentation, imaging findings, and genetic assessment, as these insights…

Identification and Surveillance of Individuals with VHL Disease

Von Hippel-Lindau (VHL) disease is a rare, heritable condition in which approximately 80% of affected individuals have an affected parent, underscoring the critical importance of early identification and surveillance. However, its rarity and variable presentation can…

The Promise of Folate Receptor Alpha-Targeting ADCs for Platinum-Resistant Ovarian Cancer

Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…

All Hands on Deck: A Focus on Current and Emerging Treatment Options in the Frontline Setting for Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…